Drug discovery and development company Engine Biosciences has raised USD 27 million in a Series A extension financing round led by Polaris Partners with participation from existing investors ClavystBio, Invus, EDBI, as well as new investors Coronet Ventures and SEEDS Capital. With this, the total funds raised by the company amounted to USD 86 million.
The company intends to use the funds to advance its biomarker and target discovery programs to clinical stages through internal development, collaborations, and partnerships.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.